Close Menu

NEW YORK (GenomeWeb) – DermTech announced today that it has raised $10 million of its Series C preferred equity offering.

"We are very pleased to have the investor support allowing us to reach $10 million in preferred stock sold out of our $15 million offering," DermTech CFO Steve Kemper said in a statement.

The company said it would use the proceeds of the offering to continue the expansion of its sales force and bring new skin cancer products to market in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.